Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor regulatory update

OGS completed the rolling submission of its NDA for Vevesca to treat Type I Gaucher disease. The company's MAA for Vevesca was accepted for review by the EMEA in July. ...